Low-molecular-weight enzyme inhibitors suppress the development of experimental allergic encephalomyelitis.
We tested the activity of low-molecular-weight enzyme inhibitors with immunomodifying actions on the suppression of experimental allergic encephalomyelitis (EAE). Of the agents tested the inhibitors of alkaline phosphatase, aminopeptidase B and esterase gave significant protection against the clinical expression of EAE in guinea pigs.
D000469:Alkaline Phosphatase / Q000037:antagonists & inhibitors*; D000626:Aminopeptidases / Q000037:antagonists & inhibitors; D000818:Animals; D002417:Cattle; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000473:pathology; D004950:Esterases / Q000037:antagonists & inhibitors; D005998:Glycine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006146:Guanidines / Q000627:therapeutic use; D006168:Guinea Pigs; D007783:Lactones / Q000627:therapeutic use; D008297:Male
D006146:Guanidines; D007783:Lactones; C016464:forphenicine; C017293:esterastin; C040039:arphamenine B; D004950:Esterases; D000469:Alkaline Phosphatase; D000626:Aminopeptidases; C019721:aminopeptidase B; D005998:Glycine